Human hematopoiesis for oral administration or injection

Abstract

The invention belongs to a blood-related product, and particularly relates to a human hematopoietic product for oral administration or injection. The main components of the human hematopoiesis comprise essential amino acids, trace elements, vitamins, nutrient substances and growth factors. The preparation method comprises the following steps: synthesizing and sub-packaging in a sterile reaction kettle, diluting with normal saline to form a diluent, mixing with lecithin emulsion, inputting into the liquid through mixed gas of medical sterile pure O2 and O3 to enable the oxygen partial pressure to reach more than 95Kpa, filling into an infusion bag at equal pressure to prepare a hematopoietic finished product, and after the hematopoietic finished product is inspected to be qualified through pyrogen, obtaining the medicine for clinical human body infusion or oral administration. The hematopoietic carbonized fluorine-free compound is prepared from a safe and nontoxic lecithin emulsion; the emulsion which has oxygen carrying capacity, is not limited by blood types, can be stored for a long time, is free of mixing of bacteria or viruses and promotes growth of the hematopoietic stem cells is obtained by diluting a diluent of amino acid, trace elements, vitamins, nutrient substances and growth factors and injecting oxygen at overhigh pressure. The growth factors further promote synthesis of hematopoietic stem cells and division of hemoglobin, the blood recovery capacity is improved through the synergistic effect of multiple raw materials, and the composition is especially suitable for ischemia symptoms such as iron deficiency type anemia.

Description

technical field [0001] The invention belongs to a blood-related product, in particular to an artificial blood for oral or injection. Background technique [0002] According to the statistics of the World Health Organization, there are 117.4 billion units of donated blood in the world every year, but this amount is far from enough for clinical use. Range has been exploring human blood substitutes since the last century, hoping to solve the blood shortage and avoid blood transfusion-transmitted diseases through artificial blood. Scientists use fluorocarbons, fluorosol emulsion DA, and use stem cells to produce artificial blood, but the amount of culture can not meet the needs of blood transfusion, and researchers have not yet successfully developed real blood; the fluorine developed by Shanghai Institute of Organic Chemistry Carbon artificial blood uses fluorocarbons as raw materials to prepare fluorocarbon emulsions that are similar to human blood's pH, various electrolytes,...

AI Technical Summary

Problems solved by technology

[0007] In the prior art, artificial blood mainly replaces some functions of human blood, such as hemoglobin or hemoglobin+platelets, thereby temporarily replacing part of the blood. It is mainly used for urgently needed blood for wounded operations, which cannot improve the hematopoietic ability of the present application. And it is impossible to completely replace blood, and its additives need to be excreted from the body for several weeks

In the prior art, there is no direct injection or oral administration to promote the production of more hematopoietic stem cells in the human body's own bone marrow, so as to differentiate into red blood cells, white blood cells, platelets, etc., to improve its own hematopoietic function

Images